Transcription of GUIDELINES FOR BIOAVAILABILITY & BIOEQUIVALENCE …
{{id}} {{{paragraph}}}
GUIDELINES FOR BIOAVAILABILITY & BIOEQUIVALENCE STUDIES Central Drugs Standard Control Organization, Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, New Delhi. (March 2005) These GUIDELINES should be read in conjunction with Schedule Y to the Drugs and Cosmetic Rules, GCP GUIDELINES issued by CDSCO, Ministry of Health and Family Welfare, GLP and the Ethical GUIDELINES for Biomedical research on human subjects issued by Indian Council of Medical Research. All provisions described in above documents shall appropriately apply to the conduct of BIOAVAILABILITY and BIOEQUIVALENCE studies.
3 1. INTRODUCTION Ensuring uniformity in standards of quality, efficacy and safety of pharmaceutical products is the fundamental responsibility of CDSCO.
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}
Clinical development of fixed combination, Clinical development of fixed combination medicinal products containing, Medicinal products, Similar, Handbook for good clinical research practice, WHO monographs on selected medicinal plants, Public Assessment Report UKPAR Thiamine, Products, Glycopyrronium bromide, Glycopyrronium, FOR SUBMITTING APPLICATION FOR